Literature DB >> 1655983

Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome.

D Boucquey1, C J Sindic, M Lamy, M Delmée, J P Tomasi, E C Laterre.   

Abstract

We retrospectively reviewed the clinical files of 45 Guillain-Barré syndrome (GBS) patients admitted to our Department between 1979 and 1989. The age distribution was bimodal with a first peak in young adults (20-40 years), and a second one between 60 to 70 years. Seasonal distribution showed a late fall and a hivernal predominance. Three patients experienced a second attack of GBS 2-9 years after the first one. Thirty-one (69%) presented antecedent events, most often a respiratory tract infection (n = 20) or enteritis (n = 6). Serological studies were systematically performed, including antibody titers against herpes simplex virus, Epstein-Barr virus, cytomegalovirus (CMV), respiratory syncytial virus, human immunodeficiency virus, Mycoplasma pneumoniae, Campylobacter jejuni/coli and cardiolipin. These studies showed the presence of antibodies indicative of a CMV primary infection in 22% cases and of a Campylobacter jejuni/coli infection in 13%. Co-infection was observed in 3 cases. Serology remained negative in 12 patients with a preceding respiratory infection. There was no correlation between serology and the severity of the disease. Absence of antecedent events and of positive anti-infectious serology was observed in only 10 patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655983     DOI: 10.1016/0022-510x(91)90216-t

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

2.  Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients.

Authors:  R K Lyu; L M Tang; S Y Cheng; W C Hsu; S T Chen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

3.  Guillain-Barré syndrome in Stockholm County, 1973-1991.

Authors:  G X Jiang; Q Cheng; A Ehrnst; H Link; J de Pedro-Cuesta
Journal:  Eur J Epidemiol       Date:  1997-01       Impact factor: 8.082

4.  Improved serological diagnosis stresses the major role of Campylobacter jejuni in triggering Guillain-Barré syndrome.

Authors:  Ruprecht Schmidt-Ott; Holger Schmidt; Sylvia Feldmann; Felicitas Brass; Bernd Krone; Uwe Gross
Journal:  Clin Vaccine Immunol       Date:  2006-07

5.  Epidemiology of Campylobacter jejuni isolated from patients with Guillain-Barré and Fisher syndromes in Japan.

Authors:  Masaki Takahashi; Michiaki Koga; Keiko Yokoyama; Nobuhiro Yuki
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Guillain-Barré syndrome in children.

Authors:  Faruk Incecik; M Ozlem Hergüner; Sakir Altunbasak
Journal:  Neurol Sci       Date:  2010-10-16       Impact factor: 3.307

7.  Detection of Campylobacter jejuni by culture and real-time PCR in a French cohort of patients with Guillain-Barre syndrome.

Authors:  Valérie Sivadon-Tardy; David Orlikowski; Raphael Porcher; Esthel Ronco; Christiane Caudie; Jacqueline Roussi; Jean-Louis Fauchère; Francis Mégraud; Helen Tabor; Tarek Sharshar; Djillali Annane; Jean-Claude Raphaël; Jean-Louis Gaillard
Journal:  J Clin Microbiol       Date:  2010-04-21       Impact factor: 5.948

8.  Molecular mimicry and the autoimmune response to the peripheral nerve myelin P0 glycoprotein.

Authors:  M Adelmann; C Linington
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

9.  Demonstration of Borrelia burgdorferi infection in a child with Guillain-Barré syndrome.

Authors:  G Horneff; H I Huppertz; K Müller; T Voit; H Karch
Journal:  Eur J Pediatr       Date:  1993-10       Impact factor: 3.183

10.  Myelin- and microbe-specific antibodies in Guillain-Barré syndrome.

Authors:  J Terryberry; M Sutjita; Y Shoenfeld; B Gilburd; D Tanne; M Lorber; I Alosachie; N Barka; H C Lin; P Youinou
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.